We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Boston Scientific (BSX) Outpaced the Stock Market Today
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed the most recent trading day at $91.07, moving +1.35% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 1.1%. Elsewhere, the Dow saw an upswing of 0.91%, while the tech-heavy Nasdaq appreciated by 1.35%.
Shares of the medical device manufacturer have appreciated by 0.68% over the course of the past month, outperforming the Medical sector's loss of 3.78% and the S&P 500's gain of 0.22%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. In that report, analysts expect Boston Scientific to post earnings of $0.65 per share. This would mark year-over-year growth of 18.18%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.4 billion, up 18.15% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.46 per share and revenue of $16.59 billion. These totals would mark changes of +20% and +16.48%, respectively, from last year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Boston Scientific. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Boston Scientific boasts a Zacks Rank of #2 (Buy).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 36.53. This indicates a premium in contrast to its industry's Forward P/E of 24.72.
Also, we should mention that BSX has a PEG ratio of 2.65. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BSX's industry had an average PEG ratio of 2.3 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 130, positioning it in the bottom 49% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Boston Scientific (BSX) Outpaced the Stock Market Today
Boston Scientific (BSX - Free Report) closed the most recent trading day at $91.07, moving +1.35% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 1.1%. Elsewhere, the Dow saw an upswing of 0.91%, while the tech-heavy Nasdaq appreciated by 1.35%.
Shares of the medical device manufacturer have appreciated by 0.68% over the course of the past month, outperforming the Medical sector's loss of 3.78% and the S&P 500's gain of 0.22%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. In that report, analysts expect Boston Scientific to post earnings of $0.65 per share. This would mark year-over-year growth of 18.18%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.4 billion, up 18.15% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.46 per share and revenue of $16.59 billion. These totals would mark changes of +20% and +16.48%, respectively, from last year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Boston Scientific. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Boston Scientific boasts a Zacks Rank of #2 (Buy).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 36.53. This indicates a premium in contrast to its industry's Forward P/E of 24.72.
Also, we should mention that BSX has a PEG ratio of 2.65. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BSX's industry had an average PEG ratio of 2.3 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 130, positioning it in the bottom 49% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.